




RealRate

PHARMACEUTICAL 2012

Vanda Pharmaceuticals Inc
Rank 128 of 196



The relative strengths and weaknesses of Vanda Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Vanda Pharmaceuticals Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is 178%, being 57% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	153,501
Cost of Goods Sold	0
Intangible Assets	8,027
Liabilities, Current	31,619
Liabilities, Non-Current	0
Other Assets	20,126
Other Compr. Net Income	0
Other Expenses	1,051
Other Liabilities	117,525
Other Net Income	461
Other Revenues	31,270
Property and Equipment	964
Research and Development	28,996
Selling, General and Administrative Expense	11,486

Output Variable	Value in 1000 USD
Assets	182,618
Liabilities	149,144
Expenses	41,533
Revenues	31,270
Stockholders Equity	33,474
Net Income	-9,802
Comprehensive Net Income	-9,802
BaseVar	202,513
ECR before LimitedLiability	38%
Economic Capital Ratio	178%